ENCODE, a massive effort to characterize the functional elements of the human genome, went public with its findings last week. For industry, the data are likely to spark a re-examination of genomewide association study results. Companies best positioned to take rapid advantage of the findings are those with knockdown technologies able to screen for biological effects of genes the consortium flagged as key disease players.